ArticleRespiratory research2026
Plasma extracellular vesicles-derived MicroRNAs as potential biomarkers in idiopathic pulmonary fibrosis.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ellagic acid from the traditional Chinese medicinal herb Scutellaria barbata may accelerates apoptosis in hepatic stellate cells during liver fibrosis via inhibiting miR-182-5p.Molecular and cellular biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with limited treatment options. Despite antifibrotic therapies, IPF prognosis remains poor, with a variable clinical course. IPF pathogenesis involves recurrent epithelial injury, dysregulated wound healing, and fibroblast activation, leading to excessive extracellular matrix deposition. MicroRNAs (miRNAs) are small regulatory RNAs that modulate gene expression and have been implicated in fibrotic pathways. Encapsulated within plasma-derived extracellular vesicles (EVs), miRNAs are stabilized and transported through the bloodstream, enabling non-invasive access to disease biomarkers for lung pathology.
methodsPlasma samples were obtained from 25 patients with IPF and 8 healthy controls, and the expression of plasma-derived EV miRNAs was analyzed using small RNA sequencing. The functional roles of selected miRNAs were further investigated in human alveolar epithelial cells (A549) and human normal lung fibroblast cells (NHLF) through in vitro experiments.
resultsEV miRNA levels were significantly elevated in patients with IPF. Differential expression analysis revealed upregulation of miR-146b-5p, miR-182-5p, and miR-199a-3p and downregulation of miR-92a-3p in the IPF group. Pathway analysis of predicted target genes indicated enrichment in biological processes relevant to IPF pathogenesis, including epithelial proliferation, wound healing, Wnt signaling, and immune regulation. In vitro experiments further demonstrated that overexpression of plasma-derived EV miRNAs modulated fibrogenic marker expression by either enhancing or suppressing TGF-β signaling, depending on the specific miRNA.
conclusionsThese findings indicate that the identified miRNAs might be involved in fibrotic responses in lung resident cells and may have potential as non-invasive biomarkers, providing preliminary mechanistic insights into the pathogenesis of IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.